- Previous Close
1,357.90 - Open
1,320.05 - Bid 1,328.00 x --
- Ask 1,328.00 x --
- Day's Range
1,305.15 - 1,352.50 - 52 Week Range
1,225.00 - 1,580.00 - Volume
29,960 - Avg. Volume
108,055 - Market Cap (intraday)
251.528B - Beta (5Y Monthly) --
- PE Ratio (TTM)
44.25 - EPS (TTM)
30.01 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1,663.33
Emcure Pharmaceuticals Limited engages in the developing, manufacturing, and marketing pharmaceutical products worldwide. It offers products in various therapeutic areas, such as gynecology, cardiovascular, anti-infectives, HIV antivirals, respiratory, gastrointestinal, pain and analgesics, blood related, oncology/anti-neoplastics, anti-diabetic, hormones, neurology/central nervous system, dermatology, and other areas, as well as vitamins, minerals, and nutrients. The company also develops products across various platforms, including chiral molecules, complex APIs, orals, iron products, photo-chemistry products, liposomal and lyophilized injectables, high potency drugs, biotherapeutics, and novel drug delivery systems. It provides its products under Orofer, Bevon, Maxtra, Zostum, Metpure, and Eslo brand names. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
www.emcure.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: EMCURE.NS
View MorePerformance Overview: EMCURE.NS
Trailing total returns as of 1/13/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EMCURE.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EMCURE.NS
View MoreValuation Measures
Market Cap
256.75B
Enterprise Value
265.32B
Trailing P/E
45.27
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.58
Price/Book (mrq)
6.25
Enterprise Value/Revenue
3.70
Enterprise Value/EBITDA
18.86
Financial Highlights
Profitability and Income Statement
Profit Margin
7.82%
Return on Assets (ttm)
8.06%
Return on Equity (ttm)
16.49%
Revenue (ttm)
72.56B
Net Income Avi to Common (ttm)
5.67B
Diluted EPS (ttm)
30.01
Balance Sheet and Cash Flow
Total Cash (mrq)
2.32B
Total Debt/Equity (mrq)
27.62%
Levered Free Cash Flow (ttm)
2.58B